Zurcher Kantonalbank Zurich Cantonalbank Sells 3,810 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Zurcher Kantonalbank Zurich Cantonalbank reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 10.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,866 shares of the company's stock after selling 3,810 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in IDEXX Laboratories were worth $13,175,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in IDEXX Laboratories by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after buying an additional 40,349 shares during the period. Franklin Resources Inc. grew its position in IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after acquiring an additional 34,305 shares during the last quarter. Amundi boosted its stake in shares of IDEXX Laboratories by 8.1% during the fourth quarter. Amundi now owns 758,669 shares of the company's stock valued at $328,018,000 after purchasing an additional 56,837 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of IDEXX Laboratories by 0.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock valued at $379,875,000 after purchasing an additional 2,463 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of IDEXX Laboratories by 3.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company's stock valued at $219,823,000 after purchasing an additional 16,213 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts recently commented on IDXX shares. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler upped their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Stock Up 2.2 %

IDXX traded up $9.01 during midday trading on Friday, reaching $415.30. The company's stock had a trading volume of 645,193 shares, compared to its average volume of 549,297. The stock's 50-day moving average is $438.03 and its 200-day moving average is $447.00. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $33.78 billion, a price-to-earnings ratio of 38.92, a PEG ratio of 3.41 and a beta of 1.39.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.18% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.